Clinical trials: Allergen Immunotherapy
Hay Fever
Safety of gpASIT+TM Subcutaneously Administered to Hay Fever Patients With or Without Immunoregulating Adjuvant
The aim of the study is to compare the safety, clinical tolerability, immunogenicity and efficacy of gpASIT+TM (grass pollen peptides) alone and combined with an immunoregulating adjuvant, in a short course administration (5…
- Trial name
- NCT01506375
- Testing
- gpASIT+TM, gpASIT+TM + adjuvant
- Where
- Belgium
- Volunteers
- 24 people
- Sponsor
- BioTech Tools S.A.
Allergic Rhinitis
Efficacy and Safety of Sublingual Immunotherapy (SLIT)
The purpose of this study is to evaluate the efficacy and safety of specific sublingual immunotherapy (SLIT) with allergen extracts in patients suffering from seasonal allergic rhinitis .
- Trial name
- NCT01012882
- Testing
- sublingual immunotherapy with allergen extract
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- Roxall Medizin
Pollen Allergy
Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of Birch Pollen Allergens
The aim of this clinical trial is to show safety and efficacy of the allergoid preparation of birch pollen allergens in the treatment of birch allergic patients in a representative number of patients.
- Trial name
- NCT00263627
- Testing
- Birch pollen allergoid
- Where
- Germany
- Volunteers
- 253 people
- Sponsor
- Allergopharma GmbH & Co. KG
Grass Allergy, Rhinoconjunctivitis
ToleroMune Grass Follow on Study
Grass pollen allergens are recognised as a major cause of allergic diseases in humans and animals. Worldwide, at least 40% of allergic patients are sensitised to grass pollen allergens and between 50-90% of hayfever or seasonal…
- Trial name
- NCT01923779
- Volunteers
- 163 people
- Sponsor
- Circassia Limited
Peanut Allergy
Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents
To compare the HRQOL of AR101 characterized oral desensitization immunotherapy (CODIT™) in combination with standard of care (peanut avoidance, education) versus standard of care alone in peanut-allergic subjects aged 4 to 17…
- Trial name
- NCT03703791
- Testing
- AR101
- Where
- 11 sites in Spain
- Volunteers
- 1 people
- Sponsor
- Aimmune Therapeutics, Inc.
Birch Pollen Allergy
Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV
Specific immunotherapy with recombinant birch pollen allergen rBet v1-FV
- Trial name
- NCT00266526
- Testing
- Recombinant birch pollen
- Where
- Germany
- Sponsor
- Allergopharma GmbH & Co. KG
Allergic Rhinitis
Efficacy and Safety of Specific Immunotherapy With CLUSTOID Grass Pollen
The objective of this study is to assess the efficacy and safety of cluster immunotherapy with highly polymerized allergen extracts.
- Trial name
- NCT01012531
- Testing
- Subcutaneous injections with highly polymerized allergen extract
- Where
- Germany
- Volunteers
- 121 people
- Sponsor
- Roxall Medizin
Grass Pollen Allergy
Safety and Dose Finding Trial of BM32 in Subjects Suffering From Grass Pollen Allergy
The study will evaluate the dose response of immunotherapy against grass pollen allergy using the recombinant grass pollen vaccine BM32.
- Trial name
- NCT01445002
- Testing
- BM32
- Where
- Austria
- Volunteers
- 79 people
- Sponsor
- Biomay AG
Cat Allergy, Rhinoconjunctivitis
An Optional Two Year Follow Up Study to Study CP005A
Cat allergy is an increasingly prevalent condition affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma.
- Trial name
- NCT01604018
- Where
- Canada
- Volunteers
- 51 people
- Sponsor
- Circassia Limited
Peanut Allergy
Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT
This is a multi-center, randomized, double-blind placebo controlled study of efficacy and safety of characterized peanut oral immunotherapy in peanut allergic individuals.
- Trial name
- ARC001 (NCT01987817)
- Testing
- AR101 powder provided in capsules
- Where
- 8 sites in United States
- Volunteers
- 56 people
- Sponsor
- Aimmune Therapeutics, Inc.
Grass Allergy, Rhinoconjunctivitis
ToleroMune Grass Exposure Unit Study
Grass pollen allergens are recognised as a major cause of allergic diseases in humans and animals. Worldwide, at least 40% of allergic patients are sensitised to grass pollen allergens and between 50-90% of hayfever or seasonal…
- Trial name
- NCT01385800
- Testing
- ToleroMune Grass
- Where
- Canada
- Volunteers
- 280 people
- Sponsor
- Circassia Limited
Allergic Rhinitis
Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis
The purpose of this study is to assess the efficacy of two doses of sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily over a period of 12 months compared to placebo, for reduction of allergic…
- Trial name
- NCT00674700
- Testing
- 300 IR house dust mites allergen extract tablet, 500 IR house dust mites allergen extract tablet
- Volunteers
- 509 people
- Sponsor
- Stallergenes Greer
Abortion, Recurrent
Role of Hypersensitivity to Female Sex Hormones in Women With Unexplained Recurrent Pregnancy Loss
The EVE- technology is intended for determination of intolerance or sensitivity to female sex hormones among women with hormone-related conditions and for further treatment by desensitization procedure inducing a tolerance to the…
- Trial name
- NCT01175759
- Testing
- Skin test panel
- Where
- Hungary
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- EVE Medical Systems Ltd.
Premenstrual Syndrome
Evaluation of Efficacy/Safety of EVE-PMS Skin Test Panel
The EVE-PMS technology is intended for determination of intolerance or sensitivity to sex hormones, among women suffering from severe PreMenstrual Syndrome (PMS).
- Trial name
- NCT00866437
- Testing
- Skin test panel
- Where
- Israel
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- EVE Medical Systems Ltd.